Procalcitonin as a Biomarker for Predicting Amputation Level in Lower Extremity Infections

Reiner, Matthew M.; Khoury, Wissam; Canales, Michael B.; Chmielewski, Richard; Patel, Kartick; Razzante, Mark C.; Cloughtery, Coleman O.; Rowland, Douglas Y.

doi:10.1053/j.jfas.2017.01.014

Cited by 23 publications

(16 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Around 20% of patients with IDFU undergo lower extremity amputation . In a study reported by Reiner et al patients with elevated PCT levels at baseline were more likely to require subsequent amputations. Conversely, although Karakas et al could not find significant PCT and CRP differences between patients who did or did not have amputation, a significant elevation in ESR was found ( P = 0.042).…”

Section: Discussionmentioning

confidence: 95%

Pentraxin‐3: A new parameter in predicting the severity of diabetic foot infection?

Balın

Tartar

Uğur

et al. 2019

International Wound Journal

View full text Add to dashboard Cite

This study was undertaken to evaluate the diagnostic and prognostic values of pentraxin‐3 (PTX‐3) in patients with infected diabetic foot ulcers (IDFU) as well as to assess the association between PTX‐3 levels and IDFU severity. This study included 60 IDFU patients (Group 1), 45 diabetic patients without DFU (Group 2), and 45 healthy controls. Patients with IDFU were divided into mild, moderate, and severe subgroups based on classification of clinical severity. Patients who underwent amputation were also documented. Blood samples were collected to determine PTX‐3 levels. PTX‐3 levels in healthy controls, Group 1, and Group 2 were 5.83 (3.41‐20) ng/mL, 1.47 (0.61‐15.13) ng/mL, and 3.26 (0.67‐20) ng/mL, respectively. A negative correlation between plasma PTX‐3 and glucose levels was found. There were significant differences in terms of procalcitonin (PCT) and PTX‐3 levels in the subgroup analysis of Group 1. The PTX‐3 level in patients who did or did not undergo amputation was 4.1 (0.8‐13.7) and 1 (0.6‐15.1) ng/mL, respectively. Results suggest that PTX‐3 is a particularly effective marker in patients with IDFU, both in terms of predicting disease severity and assisting in the decision to perform amputation.

show abstract

Section: Discussionmentioning

confidence: 95%

Pentraxin‐3: A new parameter in predicting the severity of diabetic foot infection?

Balın

Tartar

Uğur

et al. 2019

International Wound Journal

View full text Add to dashboard Cite

show abstract

“…Another predictor of DFU healing and LEA which has recently been revealed is HDL (64). Likewise, procalcitonin has been agreed as a biomarker associated with DFU infection signs (65,66), due to its sensitivity as well as specificity in evaluating infected DFU (67,68). Moreover, pH of wound fluid measurements also help clinical nurses in assessing infection along with predicting DFU healing (69,70).…”

Section: Nursing Fieldmentioning

confidence: 99%

Diabetic foot ulcer care: a concept analysis of the term integrated into nursing practice

Subrata

Phuphaibul

2019

Scandinavian Caring Sciences

View full text Add to dashboard Cite

Background Diabetic foot ulcer care demonstrates a beneficial approach to overcoming problems in patients with diabetes. This approach is frequently given but is not always successfully implemented due to its fragmentation amid healthcare providers. What's more, there are a number of different understandings, interchangeable languages and an absence of uniformity overlapping terminologies of meaning for diabetic foot ulcer care. Therefore, analysing the concept of diabetic foot ulcer care is important to provide a wider nursing knowledge, synthesise a greater theoretical model and drive more effective care of diabetic foot ulcer. Objective This article aimed to analyse how the concept of diabetic foot ulcer care is clearly defined in the relevant evidence as it has several implications in nursing practice. Method Walker and Avant's (1995) method of concept analysis was systematically used in this study. Findings Three critical attributes of diabetic foot ulcer care were determined consisting of assessment, intervention and evaluation. Constructed cases are also presented to differentiate the concept of diabetic foot ulcer care from other concepts. This concept analysis results in the critical attributes of diabetic foot ulcer care, defines an operational definition and describes common goals that improve clarity, consistency and understanding of the concept amid healthcare professionals along with researchers. Conclusion Effective implementation of the concept of DFU care into clinical nursing practice may undoubtedly improve patient outcomes and prevent the complexities of DFU in the years to come. Future research needs to be developed for evaluating the current use of this concept.

show abstract

“…Recent clinical studies have shown that procalcitonin as an inflammatory biomarker had a pretty accurate diagnostic ability to sepsis, shock, bacterial complications of some diseases (Hayashida et al, 2017;Morgenthaler et al, 2006;Reiner et al, 2017;Remde et al, 2016;Simon et al, 2004). Additionally, this biomarker may help to manage the patients with HF when antibiotic use is needed or the critical state has been verified (Ryu et al, 2015).…”

Section: Procalcitoninmentioning

confidence: 99%

Up-to-date clinical approaches of biomarkers’ use in heart failure

Berezin¹

2017

Biomed. Res. Ther.

View full text Add to dashboard Cite

Heart failure (HF) is considered a leading cause of death in patients with established cardiovascular (CV) and metabolic diseases. Although current treatment strategy has improved survival rate and clinical outcomes of HF, the HF prevalence exhibits growth especially in older patients' population and survivors after coronary atherothrombotic events. Current clinical guidelines regarding treatment and prevention of HF claim the role of biological markers as pretty easy and powerful tool for diagnosis, risk stratification, and prognostication of HF. However, there is not clear whether all these biological markers are able to equally predict CV death and HF-related outcomes in patients with acute and chronic HF as well as in various phenotypes of HF. The aim of the review is to discuss a role of in risk stratification and individual treatment in patients with different phenotypes of HF.

show abstract

Procalcitonin as a Biomarker for Predicting Amputation Level in Lower Extremity Infections

Cited by 23 publications

References 28 publications

Pentraxin‐3: A new parameter in predicting the severity of diabetic foot infection?

Pentraxin‐3: A new parameter in predicting the severity of diabetic foot infection?

Diabetic foot ulcer care: a concept analysis of the term integrated into nursing practice

Up-to-date clinical approaches of biomarkers’ use in heart failure

Contact Info

Product

Resources

About